Targeting T-cell costimulation to the surface of tumor cells.

Autor:	Eguren-Santamaría I; Navarra Institute for Health Research (IdiSNA), Spain., Sanmamed MF; Clinica Universidad de Navarra, Pamplona, Spain., Molero-Glez P; Clinica Universidad de Navarra, CIBERONC, Pamplona, Navarra, Spain., Perez-Gracia JL; Clinica Universidad de Navarra, Pamplona, Spain., Melero I; Clinica Universidad de Navarra, CIBERONC, Pamplona, Navarra, Spain.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
DOI:	10.1158/1078-0432.CCR-24-3003
Abstrakt:	Bispecific agents targeting tumor-cell surface antigens and activating receptors on T lymphocytes are being developed for solid tumors. Effective and safe strategies depend on target specificity and at least relative tumor-tissue confinement of T-cell activation. Novel evidence suggests that constructs targeting HER2 on tumor cells with the aim of providing costimulation (signal-2) to T lymphocytes via CD137 (4-1BB) are safe and can meaningfully invigorate antitumor responses in a proportion of patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu